Aktualnie znajdujesz się na:

Ipsen Poland became a new partner of Warsaw Health Innovation Hub

On 9th of January 2023, Ipsen Poland joined the group of partners of the Warsaw Health Innovation Hub (WHIH). The signing of the cooperation agreement took place at the headquarter of the Medical Research Agency (MRA) with the participation of Mr. Radosław Sierpinski, President of MRA and Mrs. Ioana Parsons, CEO of Ipsen Poland.

President Sierpiński emphasized that Ipsen Poland has extensive experience on the Polish market. - Ipsen Poland has been operating in our market for thirty years. It is one of the first global pharmaceutical companies that decided to open its operations in Poland after the political transformation period. The experience and reputation gained during this time, as well as the understanding of the innovative needs of the Polish medical sector, allows us to believe that Ipsen Poland will be an extremely valuable partner of the Warsaw Health Innovation Hub - said President of Medical Research Agency.

The CEO of Ipsen Poland, Mrs. Ioana Parsons, presented the main areas of the company's activity in Poland and expressed hope for close cooperation on projects implemented under the auspices of the Warsaw Health Innovation Hub. - We are extremely honored to join the Warsaw Health Innovation Hub. Thanks to this initiative, we are even more motivated to develop innovative solutions in healthcare that will help improve patients' quality of life in Ipsen’s key therapeutic areas - oncology, neurology, and rare diseases. Effective cooperation between the public and private sectors can contribute to the development of optimal solutions for patient care and can increase the overall efficiency of the Polish healthcare system - said the General Director of Ipsen Poland.

Ipsen Poland is a part of global biopharmaceutical company whose activities focus on innovative therapies in oncology, rare diseases and neurology. Ipsen Poland has been investing in the development of medicine for years, using scientific knowledge to conduct clinical trials, search for new solutions for patients and at the same time manage the life cycle of medicinal products introduced to the market.

Opcje strony

go up